These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 8970246)

  • 1. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
    Walters TR
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
    Schuman JS
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
    Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
    Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brimonidine tartrate: a one-month dose response study.
    Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
    Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
    Serle JB
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
    Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
    J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
    Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
    Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
    David R; Spaeth GL; Clevenger CE; Perell HF; Siegel LI; Henry JC; Stiles MC; Passo MS; Stamper RL; Walt JG
    Arch Ophthalmol; 1993 Oct; 111(10):1387-90. PubMed ID: 8105773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty.
    Ma YR; Lee BH; Yang KJ; Park YG
    Korean J Ophthalmol; 1999 Dec; 13(2):78-84. PubMed ID: 10761402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
    Adkins JC; Balfour JA
    Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
    Lee DA; Gornbein JA
    J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty.
    Barnebey HS; Robin AL; Zimmerman TJ; Morrison JC; Hersh SB; Lewis RA; Coleman AL; Cinotti DJ; Walt J; Chen KS
    Ophthalmology; 1993 Jul; 100(7):1083-8. PubMed ID: 8100625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
    Katz LJ
    Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
    Shi JM; Jiang YQ
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):263-6. PubMed ID: 12575311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.